Targeting Cancer Cells with Greater Accuracy
NeoPulse boosts the effectiveness of an anti-cancer drug to kill cancer cells while minimizing toxic side effects.
NeoPulse uses the OMS system to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.
Traditionally, bleomycin must be administered by intravenous infusion. Because this method targets cancer cells inefficiently, high doses must be used and significant side effects are common.
Using NeoPulse to electroporate and directly target cancerous cells with bleomycin, an effective result can be achieved with 1/20th of a traditional chemotherapy dose. In fact, by opening the cell membrane, we can enhance the drug’s ability to kill tumor cells by a factor of as much as 4,000.
Intensifying an already powerful drug
Bleomycin is proven to destroy cancer cells by attacking their DNA via an apoptotic or “suicidal” mechanism. When administered to cancer cells directly through electroporation, the efficacy of bleomycin is increased exponentially. Even more advantageous, the pores of treated cells close shortly after introduction of the drug, trapping it within. Tests show that electroporated cells retain more of the drug, and retain it for a longer period, thereby increasing the effectiveness of the treatment.
Benefits of NEOPULSE:
Reduced side effects. Only a fraction of the conventional dose is needed to achieve effective results, which reduces or eliminates painful and debilitating side effects associated with bleomycin.
Better quality of life. NeoPulse delivers a highly targeted and noninvasive therapy. The treatment is less likely to involve the removal of healthy tissue therefore not having a negative impact on quality of life.
Lower treatment costs. A pharmacoeconomic data analysis suggests that NeoPulse therapy costs significantly less and that it’s also less likely to require costly post-treatment care than surgical alternatives.
Greater treatment accessibility. Patients unable to withstand surgery or conventional chemotherapy may still be able to qualify for less invasive, electroporation-based treatment.
Extensive pre-clinical and clinical data from Phase 1 through 4 clinical trials demonstrate NeoPulse is safe and highly effective in eradicating solid tumors, including melanoma, basal cell carcinoma, squamous cell carcinoma, and liver and pancreatic cancers, with observable cancer cell destruction, better quality of life benefits, and swift healing of the wound site.
Success in killing locally recurrent or secondary primary tumor.
On average, patients who received our treatment lived 8 months (equal to surgery).
Success in killing local primary tumors without any recurrence (monitored for 8 months)